Start-Up Quarterly Statistics, Q3 2011
This article was originally published in Start Up
Biopharma start-ups raised $299 million and just over half were Series A rounds. Device companies brought in $134 million, while two diagnostics firms raised $10 million total. Ophthalmology was the most popular theracat for biopharma alliances. Just one acquisition involving a start-up took place.
You may also be interested in...
Asia Spotlight: Meet China’s New Innovators – Hua Medicine Looks To Take Flight With U.S. Venture Backing
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
Merck Out-Licenses Gene Therapy Assets To FKD Therapies
Finland's FKD Therapies set up to exploit Merck & Co's gene therapy assets, and expects to start Phase II trials of a bladder cancer therapeutic in 2012.
Belgium's Amakem Raises €18 million In Europe's Largest Series A So Far In 2011
Belgian start-up raises record-breaking €18 million A round to take rho kinase inhibitor glaucoma candidate to clinical proof-of-concept.